These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19787769)

  • 21. The population dynamics of cancer: a Darwinian perspective.
    Vineis P; Berwick M
    Int J Epidemiol; 2006 Oct; 35(5):1151-9. PubMed ID: 16987840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discarding functional residues from the substitution table improves predictions of active sites within three-dimensional structures.
    Gong S; Blundell TL
    PLoS Comput Biol; 2008 Oct; 4(10):e1000179. PubMed ID: 18833291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetaldehyde-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the FASAY (functional analysis of separated alleles in yeast).
    Paget V; Lechevrel M; Sichel F
    Mutat Res; 2008 Mar; 652(1):12-9. PubMed ID: 18242117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets.
    Anoosha P; Sakthivel R; Michael Gromiha M
    Biochim Biophys Acta; 2016 Feb; 1862(2):155-65. PubMed ID: 26581171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting the functional consequences of cancer-associated amino acid substitutions.
    Shihab HA; Gough J; Cooper DN; Day IN; Gaunt TR
    Bioinformatics; 2013 Jun; 29(12):1504-10. PubMed ID: 23620363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
    Anoosha P; Huang LT; Sakthivel R; Karunagaran D; Gromiha MM
    Mutat Res; 2015 Oct; 780():24-34. PubMed ID: 26264175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical analysis of pathogenicity of somatic mutations in cancer.
    Greenman C; Wooster R; Futreal PA; Stratton MR; Easton DF
    Genetics; 2006 Aug; 173(4):2187-98. PubMed ID: 16783027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer initiation with epistatic interactions between driver and passenger mutations.
    Bauer B; Siebert R; Traulsen A
    J Theor Biol; 2014 Oct; 358():52-60. PubMed ID: 24859427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of amino acid replacement costs by mutational pressure in bacterial genomes.
    Błażej P; Mackiewicz D; Grabińska M; Wnętrzak M; Mackiewicz P
    Sci Rep; 2017 Apr; 7(1):1061. PubMed ID: 28432324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome wide identification of recessive cancer genes by combinatorial mutation analysis.
    Volinia S; Mascellani N; Marchesini J; Veronese A; Ormondroyd E; Alder H; Palatini J; Negrini M; Croce CM
    PLoS One; 2008; 3(10):e3380. PubMed ID: 18846217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
    Chang MT; Asthana S; Gao SP; Lee BH; Chapman JS; Kandoth C; Gao J; Socci ND; Solit DB; Olshen AB; Schultz N; Taylor BS
    Nat Biotechnol; 2016 Feb; 34(2):155-63. PubMed ID: 26619011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian inference of negative and positive selection in human cancers.
    Weghorn D; Sunyaev S
    Nat Genet; 2017 Dec; 49(12):1785-1788. PubMed ID: 29106416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gain and loss of phosphorylation sites in human cancer.
    Radivojac P; Baenziger PH; Kann MG; Mort ME; Hahn MW; Mooney SD
    Bioinformatics; 2008 Aug; 24(16):i241-7. PubMed ID: 18689832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and functional restraints on the occurrence of single amino acid variations in human proteins.
    Gong S; Blundell TL
    PLoS One; 2010 Feb; 5(2):e9186. PubMed ID: 20169194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HUMAN KINASES DISPLAY MUTATIONAL HOTSPOTS AT COGNATE POSITIONS WITHIN CANCER.
    Gallion J; Wilkins AD; Lichtarge O
    Pac Symp Biocomput; 2017; 22():414-425. PubMed ID: 27896994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of post-translational modification sites in disease.
    Li S; Iakoucheva LM; Mooney SD; Radivojac P
    Pac Symp Biocomput; 2010; ():337-47. PubMed ID: 19908386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large differences in proportions of harmful and benign amino acid substitutions between proteins and diseases.
    Schaafsma GCP; Vihinen M
    Hum Mutat; 2017 Jul; 38(7):839-848. PubMed ID: 28444810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational approaches and resources in single amino acid substitutions analysis toward clinical research.
    George Priya Doss C; Chakraborty C; Narayan V; Thirumal Kumar D
    Adv Protein Chem Struct Biol; 2014; 94():365-423. PubMed ID: 24629192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.